Capital Fund Management (CFM)
NTLA icon

Capital Fund Management (CFM)’s Intellia Therapeutics NTLA Stock Holding History

Capital Fund Management (CFM)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Buy
+26,100
New +$332K ﹤0.01% 1939
2025
Q4 		– Sell
-35,400
Closed -$611K – 2560
2025
Q3 		$611K Sell
35,400
-48,100
-58% -$592K ﹤0.01% 2257
2025
Q2 		$783K Buy
+83,500
New +$686K ﹤0.01% 2077
2024
Q3 		– Sell
-16,500
Closed -$369K – 2098
2024
Q2 		$369K Sell
16,500
-67,300
-80% -$1.6M ﹤0.01% 1806
2024
Q1 		$2.31M Sell
83,800
-37,400
-31% -$1.04M 0.01% 1376
2023
Q4 		$3.7M Buy
121,200
+80,600
+199% +$2.32M 0.01% 1243
2023
Q3 		$1.28M Buy
+40,600
New +$1.58M ﹤0.01% 1550
2021
Q2 		– Sell
-11,700
Closed -$939K – 1585
2021
Q1 		$939K Buy
+11,700
New +$785K 0.01% 987

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Fund Management (CFM)'s NTLA Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Intellia Therapeutics (NTLA) stake by 278% in Q1 2026, buying an estimated $6.84M and bringing the position to 730,122 shares worth $9.36M. The position accounts for 0.04% of the portfolio, ranked #580.

Capital Fund Management (CFM) first reported a position in NTLA in Q4 2022 and has held it in 9 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Capital Fund Management (CFM) held 730,122 shares of Intellia Therapeutics worth $9.36M as of Q1 2026.
  • Capital Fund Management (CFM) bought 537,096 Intellia Therapeutics shares in Q1 2026, an estimated $6.84M.
  • Intellia Therapeutics made up 0.04% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #580 holding.
  • Capital Fund Management (CFM) first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 9 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.